ONKURE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ONKURE THERAPEUTICS, INC. (OKUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $6.58 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2021-11-12
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-09-30 was $6.58.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-06-30 was $10.89, a 310.94% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $3.15, a 31.25% increase year-over-year.
- ONKURE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $2.65.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2021-09-30 | $6.58 10-Q · filed 2021-11-12 | $3.59 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $10.89 10-Q · filed 2021-08-11 | $3.42 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $3.15 10-Q · filed 2021-05-20 | ||
| 2020-09-30 | $2.48 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $2.65 10-Q · filed 2021-08-11 | $2.51 10-Q · filed 2021-08-11 | |
| 2020-03-31 | $2.40 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |